Day: October 22, 2021

Blog article

Cerner to lay off 150 workers next month

New Cerner CEO Dr. David Feinberg on Thursday told employees that a set of layoffs will take place in November, a company spokesperson confirmed to Modern Healthcare.

Feinberg, who took the helm as Cerner’s CEO on Oct. 1 following nearly three years leading Google Health, sent an email to employees Thursday evening after noticing a comment on Reddit, according to the Kansas City Star, which first reported the news. The Reddit commenter had said they were a company employee that recently learned they would be laid off.

“You will always get transparency from me,” Feinberg wrote in the email, according to the Kansas City Star. “Although I would have liked to be the first to inform you, I can confirm, in early November, approximately 150 positions will be eliminated from their roles at Cerner. These actions are never easy.”

Cerner did not respond to questions regarding what departments would

Read More
Health News

mRNA vaccine more effective booster to ChAdOx1 nCoV-19

(HealthDay)—Use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is more effective than homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 prime-boost vaccination, according to a study published online Oct. 17 in The Lancet Regional Health: Europe.

Peter Nordström, M.D., Ph.D., from Umeå University in Sweden, and colleagues examined the effectiveness of heterologous prime-boost COVID-19 vaccination among individuals in Sweden who had received two doses of COVID-19 by July 5, 2021. The study cohort included 94,569 individuals who received heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination, 16,402 individuals who received ChAdOx1 nCoV-19/mRNA-1273 prime-boost vaccination, and 430,100 individuals who received homologous ChAdOx1 nCoV-19/ChAdOx1 nCoV-19 prime-boost vaccination. Furthermore, 180,716 individuals were selected who were unvaccinated at the vaccination date of the corresponding case.

The researchers confirmed symptomatic COVID-19 infection in 187 individuals with heterologous vaccine schedules (incidence rate, 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate, 7.1 per 100,000 person-days) during

Read More